These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. Migita K; Koga T; Komori A; Torigoshi T; Maeda Y; Izumi Y; Sato J; Jiuchi Y; Miyashita T; Yamasaki S; Kawakami A; Nakamura M; Motokawa S; Ishibashi H J Rheumatol; 2011 Nov; 38(11):2309-17. PubMed ID: 21844139 [TBL] [Abstract][Full Text] [Related]
3. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib. Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543 [TBL] [Abstract][Full Text] [Related]
5. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Rosengren S; Corr M; Firestein GS; Boyle DL Ann Rheum Dis; 2012 Mar; 71(3):440-7. PubMed ID: 22121136 [TBL] [Abstract][Full Text] [Related]
6. The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells. Weston S; Macdonald JL; Williams LM; Roussou E; Kang NV; Kiriakidis S; Taylor PC Clin Exp Rheumatol; 2022 Sep; 40(9):1620-1628. PubMed ID: 34665696 [TBL] [Abstract][Full Text] [Related]
7. CYT387 Inhibits the Hyperproliferative Potential of Fibroblast-like Synoviocytes via Modulation of IL-6/JAK1/STAT3 Signaling in Rheumatoid Arthritis. Srivastava S; Samarpita S; Ganesan R; Rasool M Immunol Invest; 2022 Aug; 51(6):1582-1597. PubMed ID: 34704880 [TBL] [Abstract][Full Text] [Related]
8. Leptin stimulates interleukin-6 production via janus kinase 2/signal transducer and activator of transcription 3 in rheumatoid synovial fibroblasts. Muraoka S; Kusunoki N; Takahashi H; Tsuchiya K; Kawai S Clin Exp Rheumatol; 2013; 31(4):589-95. PubMed ID: 23622344 [TBL] [Abstract][Full Text] [Related]
9. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Choe JY; Park KY; Park SH; Lee SI; Kim SK Arthritis Res Ther; 2013 Feb; 15(1):R26. PubMed ID: 23406906 [TBL] [Abstract][Full Text] [Related]
10. Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Ikari Y; Isozaki T; Tsubokura Y; Kasama T Cells; 2019 Jun; 8(6):. PubMed ID: 31181818 [No Abstract] [Full Text] [Related]
11. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. Li WQ; Dehnade F; Zafarullah M J Immunol; 2001 Mar; 166(5):3491-8. PubMed ID: 11207308 [TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 on RANKL expression in fibroblast-like synoviocytes and osteoclast-like cell formation induced by IL-22 in rheumatoid arthritis. Wen H; Liu Y; Li J; Wei D; Liu D; Zhao F Clin Exp Rheumatol; 2018; 36(5):798-805. PubMed ID: 29465363 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production. Migita K; Miyashita T; Izumi Y; Koga T; Komori A; Maeda Y; Jiuchi Y; Aiba Y; Yamasaki S; Kawakami A; Nakamura M; Ishibashi H BMC Immunol; 2011 Aug; 12():51. PubMed ID: 21884580 [TBL] [Abstract][Full Text] [Related]
14. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Hintzen C; Quaiser S; Pap T; Heinrich PC; Hermanns HM Arthritis Rheum; 2009 Jul; 60(7):1932-43. PubMed ID: 19565514 [TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors inhibit angiogenesis by reducing VEGF production from rheumatoid arthritis-derived fibroblast-like synoviocytes. Anjiki K; Hayashi S; Ikuta K; Suda Y; Kamenaga T; Tsubosaka M; Kuroda Y; Nkano N; Maeda T; Tsumiyama K; Matsumoto T; Kuroda R; Matsubara T Clin Rheumatol; 2024 Nov; 43(11):3525-3536. PubMed ID: 39302595 [TBL] [Abstract][Full Text] [Related]
16. STAT3 Mediates the Differential Effects of Oncostatin M and TNFα on RA Synovial Fibroblast and Endothelial Cell Function. Hanlon MM; Rakovich T; Cunningham CC; Ansboro S; Veale DJ; Fearon U; McGarry T Front Immunol; 2019; 10():2056. PubMed ID: 31555281 [No Abstract] [Full Text] [Related]
18. Chlorogenic acid and luteolin synergistically inhibit the proliferation of interleukin-1β-induced fibroblast-like synoviocytes through regulating the activation of NF-κB and JAK/STAT-signaling pathways. Lou L; Liu Y; Zhou J; Wei Y; Deng J; Dong B; Chai L Immunopharmacol Immunotoxicol; 2015; 37(6):499-507. PubMed ID: 26471424 [TBL] [Abstract][Full Text] [Related]
19. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Hashizume M; Hayakawa N; Mihara M Rheumatology (Oxford); 2008 Nov; 47(11):1635-40. PubMed ID: 18786965 [TBL] [Abstract][Full Text] [Related]
20. Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib. Diller M; Hasseli R; Hülser ML; Aykara I; Frommer K; Rehart S; Müller-Ladner U; Neumann E Front Immunol; 2019; 10():541. PubMed ID: 30984167 [No Abstract] [Full Text] [Related] [Next] [New Search]